ARS Pharmaceuticals (SPRY) told investors that its Neffy nasal spray did not gain expanded commercial insurance coverage in the July 1 review cycle, a setback that immediately weighed on expectations for the product’s market reach.

The setback on Neffy coverage comes after a sharp move in ARS Pharmaceuticals’ share price, with a 30-day share price return of 29.01% and a 90-day share price return of 30.61%. At the same time, the year-to-date share price return is down 8.27% and the 1-year total shareholder return has fallen 41.70%, compared with a 3-year total shareholder return of 59.46%. This suggests that recent momentum has picked up again while longer term holders still face meaningful drawdowns.

If this insurance update has you reassessing exposure to healthcare, it can be useful to see what else is moving and compare business models through 38 healthcare AI stocks

With ARS Pharmaceuticals trading at US$10.54 and sitting at a sizable discount to both the average analyst price target and the intrinsic value estimate, the key question is whether investors are seeing mispricing here or whether the market is already accounting for the company’s future growth.

Most Popular Narrative: 62% Undervalued

Compared with ARS Pharmaceuticals' last close of $10.54, the most followed narrative assigns a fair value of $27.73, framing the stock as materially discounted on that view.

The market is currently pricing ARS Pharmaceuticals (NASDAQ: SPRY) as if it is trapped in a value-destroying, single-product price war with its upcoming competitor, Aquestive Therapeutics (NASDAQ: AQST). With SPRY’s stock lingering under $10, investors are focused heavily on near-term cash burn and the impending launch of AQST’s sublingual film, Anaphylm.

However, this bearish narrative misses the structural reality of the $3B epinephrine market. neffy (SPRY) and Anaphylm (AQST) are not mortal enemies; they are a classic "disruptive duo" aligned against a single, archaic incumbent: Mylan's EpiPen. By focusing purely on a zero-sum duopoly, the market has created a textbook mispricing opportunity. Even under a highly conservative, stress-tested model, SPRY is presented here as having a path to a 3x+ valuation re-rating.

The narrative for ARS Pharmaceuticals hangs on a detailed top line build, a shift in profit margins and a future earnings multiple that is more often associated with larger growth franchises. Want to see how those moving parts combine into a single fair value number and why the discount rate matters so much here.

Result: Fair Value of $27.73 (UNDERVALUED)

However, investors still need to watch for slower than expected Neffy uptake after this coverage setback, as well as any pressure on ARS Pharmaceuticals’ margins from PBM rebate demands.

Another View on ARS Pharmaceuticals’ Valuation

The user narrative leans on a revenue build and future P/S multiple to argue that ARS Pharmaceuticals is undervalued, yet current market ratios paint a more cautious picture. The stock trades on a P/S of 10.6x versus a peer average of 9.5x and a fair ratio of 8.2x. This suggests investors are already paying a premium and leaves less room if expectations slip. This raises the question of whether the stock is truly at a discount or instead reflects a different kind of risk.

Next Steps

With such mixed sentiment around ARS Pharmaceuticals, it helps to move quickly, review the underlying drivers yourself, and decide where you stand. To see what optimism is currently built into the story, take a closer look at the 3 key rewards.

Looking for more investment ideas beyond ARS Pharmaceuticals?

Once you are clear on where you stand with ARS Pharmaceuticals, do not stop there. Broaden your watchlist with other potential ideas that might suit your approach.

• Spot potential bargains early by checking companies that currently screen as 44 high quality undervalued stocks.
• Strengthen your downside protection by focusing on businesses flagged in the 69 resilient stocks with low risk scores.
• Get ahead of the crowd by reviewing the screener containing 18 high quality undiscovered gems before others catch on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.